	LTH AND HUMAN SERVICES UG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER	DATE(6) OF INSPECTION		
60 Eighth Street NE	01/12/2015 - 01/16/2015		
Atlanta, GA 30309	PEI NUMBER		
(404) 253-1161 Fax: (404) 253-1202	3004969894		
Industry Information: www.fda.gov/oc/indu	stry		
NAME AND TITLE OF INDIVIOUAL TO WHOM REPORT ISSUED			
TO: Danny Barnes, President			
FIRMINALE	STREET ADDRESS		
Triangle Compounding	3700 Regency Pkwy Ste 140		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Cary, NC 27518-8696	Outsourcing Facility		

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

Specifically,

- 1) Your quality unit did not appropriately review the results of the aseptic process simulations for all the sterile processing technicians, dated 10/20/14, 10/23/14, 10/24/14 and 11/10/14, and as delineated in the policy titled Quality Assurance Program, effective 09/03/13.
- 2) Non-sterile wipes are utilized to clean inside the ISO 5 personal workplace hood area as delineated in standard operating procedure 5.161, Clean Room Routine Maintenance, effective 01/05/15.
- 3) There is no standard operating procedure delineating the disinfection of the non-viable particle counter device which is placed inside the ISO 5 personal workplace hood area and transported from the ISO 7 and ISO 8 areas.
- 4) Active air samples for viables are not collected inside the ISO 5 personal workplace hood area as part of the current environmental monitoring program delineated in standard operating procedure 7.110, Environmental Monitoring, effective 10/01/14.

SEE REVERSE OF THIS PAGE Viviana Matta, Investigator Marie F. Mathews, Investigator Marid. Mar

DATE (SSUED

01/16/2015

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

EMPLOYEE(S) SIGNATURE

INSPECTIONAL OBSERVATIONS

PAGE 1 OF 2 PAGES

		TH AND HUMAN SERV G ADMINISTRATION	VICES		
DISTRICT ADDRESS AND PHO			DATE(S) OF INSPECTION		
60 Eighth St Atlanta, GA			1/12/2015 - 01/16, NUMBER	/2015	
	-1161 Fax: (404) 253-1202		004969894		
Industry Information: www.fda.gov/oc/industry					
TO: Danny Barnes, President					
FIRM NAME	arics, riesident	STREET ADDRESS			
Triangle Com	pounding	3700 Regency Pkwy Ste 140			
	518-8696	Outsourcing Facility			
Tourist Trouble Control of Contro					
OBSERVATION 2					
There is no written testing program designed to assess the stability characteristics of drug products.					
Specifically,					
1) The firm's st	shility program lacks evidence that	tack solutions the	t are prepared from n	on-sterile	
1) The firm's stability program lacks evidence that stock solutions that are prepared from non-sterile active pharmaceutical ingredients and (b) (4) (for use as an					
() () ()	gredient) remain sterile for the durat	ion of the assigned			
	s for most of the stock solutions. The				
	on after filling. Examples of the form				
(b) (4)					
			, <u></u>		
OBSERVATION 3					
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.					
Specifically,					
~F,,					
Your cleaning practices for critical aseptic work areas, such as the ISO 5 workspace hood and carts					
adjacent to the workspace, are deficient in that the recommended surface contact times for application of					
the sporicidals and disinfectants are not always followed.					
	2			.0	
				ļ	
		1 0	·		
	SUBJECT TO THE SUBJECT OF THE SUBJEC	No. of the second secon	NASO VALLENTAR OF VAL		
	EMPLOYEE(S) SIGNATURE	elewana	Watta	DATE ISSUED	
SEE REVERSE	Viviana Matta, Investigator Marie F. Mathews, Investigat	or M	Da ·	01/16/2015	
OF THIS PAGE	1. Machens, Investigat	- 41/ai O.		51,10,2015	
		CTIONAL OBSERVATION	on o	PAGE 2 OF 2 PAGES	